The PLATO health economics sub-studies used local cost data and clinical data from Brazil, Canada, Germany, Greece, Holland, Mexico, Poland, and Spain to evaluate the clinical effect observed in PLATO, as well as cost considerations for treating ACS patients with BRILIQUE versus generic and branded clopidogrel. Across each country and measurement, results showed that even at a higher price, BRILIQUE is a cost-effective treatment for ACS patients compared to generic and/or branded clopidogrel.
"It's critical that we deliver solutions that demonstrate how our medications improve quality-of-life and reduce mortality, as well as alleviate the cost burden on the global healthcare system caused by hospital readmissions and expensive procedures," said Tony Zook, Executive Vice President of AstraZeneca's Global Commercial Organisation. "AstraZeneca works closely with our stakeholders, starting early in the drug development process, to effectively address their questions about the value of our medicines, in order to ensure patients will ultimately benefit from cost-effective therapeutic options."
Data for one additional AstraZeneca brand, CRESTOR (rosuvastatin) is now available in ISPOR’s Value in Health publication, and will also be presented at the group’s annual European meeting next month, along with the BRILIQUE health economics sub-studies:
- BRILIQUE health economics sub-studies for Brazil (abstract #33322), Canada (abstract #33335), Germany (abstract #32529), Greece (abstract #34099), Holland (abstract #32584), Mexico (abstract #33517), Poland (abstract #33653), and Spain (abstract #33160), will be presented Monday 7 November, 8:00-19:30
- The Archimedes model demonstrated that CRESTOR (rosuvastatin) a cholesterol-lowering medication, reduced the risk of major adverse cardiac events (MACE), as compared to atorvastatin in higher-risk patients (abstract #33997) will be presented Monday 7 November, 8:00-19:30
BRILIQUE is an oral antiplatelet treatment for ACS. BRILIQUE is a direct-acting P2Y12 receptor antagonist in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILIQUE is the first reversibly-binding oral ADP receptor antagonist to be approved for use in ACS.
In the European Union, BRILIQUE, a prescription oral antiplatelet treatment, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with ACS (unstable angina, NSTEMI, or STEMI), including patients managed medically and those who are managed with percutaneous coronary intervention (PCI) or Coronary Artery Bypass Grafting (CABG). The PLATO trial (A Study of PLATelet Inhibition and Patient Outcomes) was the pivotal phase III study that formed the basis of the EU label.
BRILIQUE is currently reimbursed in nine countries. The product is approved in 47 countries, including in the European Union under the trade name BRILIQUE and in the US, Brazil, Canada, and Australia, under the trade name BRILINTA.
BRILIQUE and BRILINTA are trademarks of the AstraZeneca group of companies.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.